15 years of allergen immunotherapy vial sterility testing

The prevalence of allergic rhinitis, atopic dermatitis, and asthma is increasing and is associated with significant morbidity and increasing health care costs. Current treatment options for allergic rhinitis are broad and generally begin with pharmacotherapy and, when practical, allergen avoidance. In the general population, approximately one-third of children and two-thirds of adults report partial or poor relief with pharmacotherapy alone.1 The next step in treatment is often initiation of subcutaneous allergen immunotherapy (AIT).

http://ift.tt/2iDf88A